Health Care • Biotechnology: Pharmaceutical Preparations
$10.38 ▼ -0.31
(-2.90%)
MKT CAP: $65.4M • VOL: 179.6K
52W L $8 52W H $310
ROARABLE / RQD
E • 33/100
PIOTROSKI
1 / 9
GOSS // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $48.5M | $114.7M | $0 |
| YoY Revenue Growth % | -57.7% | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$170.7M | -$59.9M | -$183.8M |
| Operating Margin % | -80.0% | -52.2% | — |
| Net Income (GAAP) | -$170.4M | -$56.5M | -$179.8M |
| EBITDA (Normalized) | -$170.7M | -$59.9M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$171.3M | -$3.5M | -$159.2M |
| Capital Expenditures (CapEx) | $79.0K | $0 | — |
| Free Cash Flow (FCF) | -$171.3M | -$3.5M | -$159.2M |
| FCF Margin % | -80.0% | -3.0% | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $37.7M | $46.1M | — |
| Total Debt (Short + Long Term) | — | $0 | — |
| Total Stockholders' Equity | -$122.8M | $29.5M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR GOSS.